女性健康治疗市场将迎来增长：创新、投资与全球影响-动脉网

Women's Health Therapeutics Market Poised for Growth: Innovation, Investment and Global Impact

CISION 等信源发布 2025-05-09 02:12



可切换为仅中文







'BCC Research presents an in-depth analysis of how innovations, market dynamics, regional trends and ESG strategies are shaping the

'BCC Research深入分析了创新、市场动态、区域趋势和ESG战略如何影响

$81.2 billion

812亿美元

women's health therapeutics market.'

女性健康治疗市场。

BOSTON

波士顿

，

May 8, 2025

2025年5月8日

/PRNewswire/ -- As global awareness of gender-specific medicine continues to rise, the

/PRNewswire/ -- 随着全球对性别特异性医学的认识不断提高，

women's health therapeutics market

女性健康治疗市场

is entering a pivotal era of innovation and investment. Leading pharmaceutical players—such as Pfizer Inc., Eli Lilly and Company, and F. Hoffmann-La Roche Ltd.—are accelerating the development of targeted therapies to address conditions like breast cancer, menopause, PCOS and endometriosis.

正在进入一个创新和投资的关键时代。领先的制药企业——如辉瑞公司、礼来公司和罗氏公司——正在加速开发针对乳腺癌、更年期、多囊卵巢综合症和子宫内膜异位症等疾病的靶向疗法。

According to the report, growing emphasis on personalized medicine and biologics is reshaping corporate strategies, especially as

根据报告，对个性化医疗和生物制品日益重视正重塑企业战略，尤其是随着

North America

北美

leads global expansion and emerging technologies unlock new care models. While the market is projected to grow at

引领全球扩张，新兴技术解锁新的护理模式。虽然市场预计将以

a CAGR of 5.7% from 2024 to 2029

从2024年到2029年的复合年增长率为5.7%

, stakeholders must navigate regulatory hurdles and rising treatment costs to capture long-term value. This shift marks a profound transformation in how biotech investors, manufacturers, and healthcare providers approach women's health—transitioning it from underserved to a global priority.

，利益相关者必须应对监管障碍和不断上升的治疗成本，以获取长期价值。这一转变标志着生物技术投资者、制造商和医疗保健提供者在女性健康方面方法的深刻变革——将其从服务不足转变为全球优先事项。

Market Overview: Key Insights and Forecast

市场概况：关键洞察与预测

BCC Research's latest report on

BCC Research的最新报告关于

Women's Health Therapeutics: Technologies and Global Markets

女性健康治疗：技术和全球市场

provides a comprehensive breakdown of market trends, investment dynamics, and therapeutic pipelines. The global market is expected to grow from

提供了市场趋势、投资动态和治疗管道的全面细分。全球市场预计将会从

$61.5 billion

615亿美元

in 2024 to

2024年到

$81.2 billion

812亿美元

by 2029

到2029年

, reflecting a shift toward biologics, hormonal therapies, and digital health solutions.

，反映了向生物制品、激素疗法和数字健康解决方案的转变。

The report offers strategic insights across key areas, including segmentation analysis, competitive intelligence, regulatory structures, ESG perspectives and emerging technologies that are reshaping the global women's health therapeutics industry.

该报告提供了跨关键领域的战略洞察，包括细分市场分析、竞争情报、监管结构、ESG视角以及正在重塑全球女性健康治疗行业的新兴技术。

Market Leadership in Transition

市场领导地位的过渡

The women's health therapeutics market is undergoing significant transformation, driven by an aging female population and rising demand for condition-specific treatment options. Companies like Pfizer, Eli Lilly and Novartis AG are actively investing in late-stage R&D for areas such as menopause and postmenopausal osteoporosis (.

女性健康治疗市场正在经历重大变革，这一变革由老龄化的女性人口和对特定病症治疗方案需求的不断增长所推动。辉瑞、礼来和诺华等公司正在积极投资于更年期和绝经后骨质疏松症等领域的晚期研发。

Chapter 5, Pipeline Assessment and Analysis; Chapter 8, Competitive Landscape

第五章，管道评估与分析；第八章，竞争格局

）。

The breast cancer segment remains the most dominant, supported by increasing incidence rates and continued innovation in monoclonal antibodies and biosimilars (

乳腺癌领域仍然是最主要的，受到发病率不断增加以及单克隆抗体和生物类似药持续创新的支持（

Chapter 7, Market Segmentation Analysis

第七章，市场细分分析

Emerging Technologies and Investment Trends

新兴技术与投资趋势

As outlined in

如所概述的

Chapter 4 (Emerging Technologies)

第四章（新兴技术）

, cutting-edge innovations such as gene therapy, CRISPR, and transdermal delivery platforms are opening doors for safer, more personalized treatments. These technologies are also enabling commercialization models in digital health and remote care—areas expected to see strong growth.

，基因治疗、CRISPR 和透皮递送平台等尖端创新正在为更安全、更个性化的治疗打开大门。这些技术还推动了数字健康和远程护理领域的商业化模式，这些领域预计将迎来强劲增长。

North America

北美

leads regional expansion, projected to grow from

引领区域扩张，预计增长来自

$28.4 billion

284亿美元

in 2024 to

2024年到

$37.4 billion

374亿美元

by 2029 at a 5.6% CAGR

到2029年，年均复合增长率为5.6%

(

Chapter 7, Regional Analysis

第七章，区域分析

). This growth is fueled by robust R&D infrastructure, regulatory support and access to biologics and HRT. Meanwhile,

）。这一增长得益于强大的研发基础设施、监管支持以及对生物制品和激素替代疗法 (HRT) 的可及性。同时，

Europe

欧洲

and the

和

Asia-Pacific

亚太地区

region present significant opportunities as healthcare systems modernize and policies evolve.

随着医疗体系的现代化和政策的演变，该地区呈现出巨大的机遇。

Pipeline Assessment and Analysis

管道评估与分析

Chapter 5

第五章

details how companies are diversifying pipelines across hormonal, non-hormonal and biologic therapies aimed at improving efficacy and minimizing side effects.

详细介绍了各公司如何在激素类、非激素类和生物疗法之间实现多样化，以提高疗效并尽量减少副作用。

Roche, in particular, has solidified its leadership in the U.S. market through its strong presence in the breast cancer, postmenopausal osteoporosis, menopause, endometriosis, and PCOS segments.

罗氏尤其通过其在乳腺癌、绝经后骨质疏松症、更年期、子宫内膜异位症和多囊卵巢综合症领域的强大影响力，巩固了其在美国市场的领导地位。

(Chapter 8, Competitive Landscape)

（第八章，竞争格局）

Regulatory and Access Challenges

监管和准入挑战

Chapter 3 (Market Dynamics)

第三章（市场动态）

highlights persistent barriers such as high treatment costs and slow regulatory pathways, particularly in low-income regions where access to diagnostics and therapies remains limited.

强调了持续存在的障碍，例如治疗成本高昂和监管途径缓慢，尤其是在获得诊断和治疗仍然有限的低收入地区。

Chapter 6 (Regulatory Structure)

第六章（监管结构）

explains how regional discrepancies in clinical trial approvals and intellectual property rules impact time-to-market and ROI projections for drug developers.

解释了临床试验批准和知识产权规则的地区差异如何影响药品开发人员的上市时间和投资回报率预测。

Strategic Outlook: The Road Ahead

战略展望：前进之路

According to

根据

Chapter 9 (ESG Perspective)

第9章（ESG视角）

, the industry is increasingly aligning with environmental, social and governance (ESG) goals—focusing on inclusivity in clinical trials, sustainable manufacturing, and broader access to care. Firms integrating ESG into product pipelines and geographic strategies are well-positioned to win both market share and investor confidence..

，该行业越来越与环境、社会和治理（ESG）目标保持一致——专注于临床试验的包容性、可持续制造以及更广泛的医疗可及性。将ESG融入产品管线和地理战略的公司，有望在赢得市场份额的同时获取投资者信心。

With rising awareness, policy support and a wave of therapeutic innovation, women's health is becoming central to the future of equitable, personalized healthcare. The next five years will be critical for companies to lead, adapt and innovate in this fast-evolving space.

随着意识的提高、政策的支持以及一波治疗创新，女性健康正成为公平、个性化医疗保健未来的核心。未来五年将是各公司在这一快速发展的领域中引领、适应和创新的关键时期。

Report Synopsis

报告概要

Report Metric

报告指标

Details

详情

Base year considered

基准年考虑在内

2023

Forecast period considered

考虑的预测期

2024-2029

Base year market size

基准年市场规模

$58.3 billion

583亿美元

Market size forecast

市场预测规模

$81.2 billion

812亿美元

Growth rate

增长率

CAGR of 5.7% for the forecast period of 2024-2029

2024-2029年预测期内的复合年增长率为5.7%

Segments covered

涵盖的段落

Women's Health Disorders, and Region

妇女健康障碍与地区

Regions covered

覆盖的区域

North America, Europe, Asia-Pacific, and the Rest of the World (RoW)

北美、欧洲、亚太地区和世界其他地区 (RoW)

Countries covered

覆盖的国家

U.S., Canada, Mexico, France, Germany, the U.K., Italy, Spain, Japan, India, Australia, South Korea and China

美国、加拿大、墨西哥、法国、德国、英国、意大利、西班牙、日本、印度、澳大利亚、韩国和中国

Market drivers

市场驱动因素

• Rising geriatric population of women.

• 女性老年群体的增加。

• Rising awareness of and accessibility to healthcare and advanced therapeutic products.

• 对医疗保健和先进治疗产品的认识和可及性不断提高。

• Advances in personalized medicine.

• 个性化医学的进展。

• Emerging markets.

• 新兴市场。

Additional Insights:

额外的见解：

The women's health therapeutics market is expanding rapidly, driven by increasing awareness, technological advancements, and increased attention to under-addressed conditions such as menopause, endometriosis, and polycystic ovary syndrome (PCOS).

女性健康治疗市场正在迅速扩张，这一趋势得益于人们意识的提高、技术的进步以及对更年期、子宫内膜异位症和多囊卵巢综合症（PCOS）等未被充分关注的疾病的关注增加。

Governments and healthcare organizations around the world are implementing initiatives to enhance access to women's health treatments, including funding programs for maternal care, reproductive health, and breast cancer screening.

世界各国政府和医疗组织正在实施多项举措，以提高女性健康治疗的可及性，包括为孕产妇护理、生殖健康和乳腺癌筛查提供资金支持的项目。

Market leaders include:

市场领导者包括：

AbbVie Inc.

艾伯维公司

Amgen Inc.

安进公司

Asahi Kasei Corp.

旭化成公司

AstraZeneca

阿斯利康

Bayer AG

拜耳公司

Bristol-Myers Squibb Co.

百时美施贵宝公司

Eisai Co. Ltd

卫材株式会社

。

F. Hoffmann-La Roche Ltd.

F. 霍夫曼-拉罗什有限公司

Johnson & Johnson Services Inc

强生服务公司

。

Lilly

莉莉

Merck & Co. Inc

默克公司

。

Novartis AG

诺华公司

Novo Nordisk A/S

诺和诺德公司

Pfizer Inc.

辉瑞公司

Teva Pharmaceutical Industries Ltd.

梯瓦制药工业有限公司

Navigate Uncertainty with Confidence

自信地应对不确定性

In times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we're here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape—providing you with the clarity you need to make informed decisions.

在快速变化和不确定的时期，拥有正确的洞察力可以带来巨大的不同。在BCC研究，我们在这里支持创新，帮助您保持领先。我们的定制研究报告提供了市场环境的全面、360度视角——为您提供做出明智决策所需的清晰度。

We believe that timely, expert market intelligence should be accessible to all. That's why, for a limited time, we're offering 30% off the price of any BCC Research report to help more organizations gain access to our latest data and insights..

我们相信，及时、专业的市场情报应该对所有人开放。因此，在有限的时间内，我们提供BCC研究报告30%的折扣，以帮助更多组织获取我们的最新数据和见解。

Get your

获取你的

copy of the report

报告的副本

directly from BCC Research.

直接来自BCC研究。

To request more information or complete your purchase, connect with us at

要索取更多信息或完成购买，请通过以下方式与我们联系

info@bccresearch.com

。

About BCC Research

关于BCC研究

BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.

BCC Research市场研究报告提供对市场机会的客观、公正的测量和评估。我们经验丰富的行业分析师的目标是帮助您在没有噪音和炒作的情况下做出明智的商业决策。

联系我们

Corporate HQ: 50 Milk St., Ste. 16,

公司总部：牛奶街50号，16楼，

Boston, MA

马萨诸塞州波士顿市

02109,

02109，

USA

美国

Email:

电子邮件：